Longboard Pharmaceuticals to Present at Upcoming Investor Conferences
August 03 2023 - 7:30AM
Business Wire
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
members of its leadership team will present at the BTIG Virtual
Biotechnology Conference and the Wedbush Annual PacGrow Healthcare
Conference in New York City.
Presentation Details: The conference presentations are
intended for BTIG and Wedbush clients only.
Event Title: BTIG Virtual Biotechnology Conference
Presentation Time: Monday, August 7, 2023, at 1:30PM ET
Additional Information: This conference is being hosted by
BTIG, a global financial services firm specializing in
institutional trading, investment banking, research and related
brokerage services. To join the conference, email
info@btig.com.
Event Title: Wedbush 14th Annual PacGrow Healthcare
Conference Panel Title: David vs. Goliath - How Can Orphan
Epilepsy Development Accelerate and Broaden its Reach? Panel
Presentation Time: Wednesday, August 9, 2023, at 9:30AM ET
Additional Information: Please contact your Wedbush
representative for conference details.
ABOUT LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of GPCR
research. Longboard is evaluating LP352, an oral, centrally acting
5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no
observed impact on 5-HT2B and 5-HT2A receptor subtypes, in
development for the potential treatment of seizures associated with
a broad range of developmental and epileptic encephalopathies.
Longboard is also evaluating LP659, an oral, centrally acting,
sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator,
which is in development for the potential treatment of multiple
neurological diseases.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about Longboard’s
participation in upcoming investor conferences and Longboard’s
clinical and preclinical programs and product candidates, ability
to develop product candidates and deliver medicines, and focus. For
such statements, Longboard claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Longboard’s expectations. Factors that
could cause actual results to differ materially from those stated
or implied by Longboard’s forward-looking statements are disclosed
in Longboard’s filings with the Securities and Exchange Commission
(SEC). These forward-looking statements represent Longboard’s
judgment as of the time of this release. Longboard disclaims any
intent or obligation to update these forward-looking statements,
other than as may be required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230803274904/en/
Megan E. Knight Head of Investor Relations
IR@longboardpharma.com 858.789.9283
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024